Adam J. Townsend - 03 Feb 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Commercial Officer
Signature: /s/ David Watson, attorney-in-fact for Adam Townsend
Issuer symbol: APLS
Transactions as of: 03 Feb 2023
Net transactions value: -$203,800
Form type: 4
Filing time: 06 Feb 2023, 16:35:53 UTC
Previous filing: 30 Jan 2023
Next filing: 14 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$75,450	+5,000	+7.4%	$15.09	72,932	03 Feb 2023	Direct	F1
transaction	APLS	Common Stock	Sale	$279,250	-5,000	-6.9%	$55.85	67,932	03 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-5,000	-1.7%	$0.000000	297,500	03 Feb 2023	Common Stock	5,000	$15.09	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale from an established 10b5-1 plan.
F2	This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.